Skip to main content
VERA
NASDAQ Life Sciences

Vera Q3: First TRUTAKNA Revenue of $10.3M, Net Loss Narrows to $93.7M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$31.07
Mkt Cap
$2.172B
52W Low
$23.05
52W High
$56.05
52W Position info
35% above low
Off High info
45% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

VERA sits 35% above its 52-week low of $23.05.

Summary

Vera reported its first TRUTAKNA revenue of $10.3 million in Q3 2026 with about 700 Patient Start Forms, and a net loss of $93.7 million that beat the $117.1 million consensus. Cash of $384.0 million plus a $75 million October debt draw leaves $459 million pro forma.


Key Events · Earnings and Guidance · VERA

  • First TRUTAKNA Revenue: $10.3M

    Net product revenue of $10.3 million in Q3 2026, the first quarter with product sales, versus none a year earlier. Approximately 700 Patient Start Forms received since the July 7, 2026 accelerated approval.

  • Net Loss Beats Consensus

    Net loss of $93.7 million, or $1.30 per share, versus the IBES estimate of -$117.1 million. SG&A rose to $61.4 million from $27.5 million on launch investment, while R&D fell to $41.3 million from $56.5 million as commercial manufacturing costs moved to inventory.

  • Cash and Debt Capacity

    Cash, cash equivalents and marketable securities of $384.0 million at September 30, 2026; $459 million pro forma after the $75 million October draw. Up to $350 million remains available under the debt facility, subject to conditions.

  • sBLA Filed for Full Approval

    Supplemental BLA for full approval in adults with primary IgAN submitted November 3, 2026, based on ORIGIN 3 final efficacy. Potential full approval expected mid-2027; EMA Marketing Authorisation Application planned for Q1 2027.


Analysis · VERA · Life Sciences

The investment case now hinges on converting IgAN patients onto TRUTAKNA, and the first quarter of commercial sales offers early evidence: $10.3 million in net product revenue and roughly 700 Patient Start Forms since the July 7 accelerated approval. The $93.7 million net loss came in well below the $117.1 million consensus estimate, while SG&A of $61.4 million versus $27.5 million a year ago confirms the launch spend is real. Cash of $384.0 million plus the $75 million October debt draw gives $459 million pro forma, with up to $350 million still available under the facility. That runway funds both the launch and the sBLA filed November 3 for full approval, which management expects to resolve in mid-2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VERA was trading at $31.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $23.05 to $56.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VERA - Latest Insights

VERA
Nov 05, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $29.53
Real-time Price: $25.25 info
Change: -$4.28 (-14%) info
Market Cap: $1.84B info
VERA
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $30.98
Real-time Price: $25.25 info
Change: -$5.73 (-18%) info
Market Cap: $1.84B info
VERA
Sep 15, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $38.64
Real-time Price: $25.25 info
Change: -$13.39 (-35%) info
Market Cap: $1.84B info
VERA
Sep 15, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $37.69
Real-time Price: $25.25 info
Change: -$12.44 (-33%) info
Market Cap: $1.84B info
VERA
Aug 10, 2026, 5:07 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $31.50
Real-time Price: $25.25 info
Change: -$6.25 (-20%) info
Market Cap: $1.84B info